

Communique from extra general meeting in Lipum AB

Press release: Umeå, 19 June 2021. Extra general meeting in Lipum AB (publ), corporate identity number 556813-5999 (the “Company”) was held on 18 June 2021 in Umeå by postal voting, whereby the shareholders, in accordance with the notice, primarily resolved on the following matters.

The extra general meeting appointed Åsa Hansdotter and Ingemar Kihlström as new board members and decided that the board for the period until the annual general meeting shall consist of five board members without deputies. The shareholders further decided that the board member shall receive remuneration with SEK 100,000 each. Lipum's board of directors now consists of: Ulf Björklund (chairman), Olle Hernell, Kristian Sandberg, Åsa Hansdotter and Ingemar Kihlström.

Dr Ingemar Kihlström has doctoral degree in chemistry/physiology and a docentur in toxicology from Uppsala University. He has extensive experience in drug development and the Life Science industry. Dr Kihlström has worked 15 years with research and development and business development at both Astra AB and Pharmacia AB followed by a 10-year career as pharmaceutical analyst in the finance industry at Swedbank, Aros Securities and ABG Sundal Collier. Ingemar has the latest 20 years worked both as Chairman and Director on the board of more than thirty companies and Dr Kihlström is currently on the board of several listed companies, mainly on Nasdaq First North in Stockholm.

Åsa Hansdotter is an attorney-at-law and partner of the business law firm HWF Advokater AB in Helsingborg. She works with company and equity capital markets law, Swedish and international M&A and further handles corporate commercial matters as external legal counsel for listed and non-listed companies within the industry and life science sectors among others. During 2001-2017, Åsa was with Mannheimer Swartling, 2010-2017 as a partner. Åsa is a board member in i.a. Dizlin Pharmaceuticals AB, P Capital Partners AB and the Swedish Chamber of Commerce for Russia & CIS.

For further information, please contact:

Einar Pontén, CEO

E-post: einar.ponten@lipum.se

Mobile: +46 70 5783495

Web: www.lipum.se

Lipum AB (publ)

The Board of Directors

About Lipum

Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: ca@gwkapital.se, phone: +46 8 503 000 50.